<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33827958</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1526-632X</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>16</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>20</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Association of Cortical Hyperexcitability and Cognitive Impairment in Patients With Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>e2090</StartPage><EndPage>e2097</EndPage><MedlinePgn>e2090-e2097</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/WNL.0000000000011798</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To determine whether cortical hyperexcitability was more prominent in cognitively impaired patients with amyotrophic lateral sclerosis (ALS).</AbstractText><AbstractText Label="METHODS">Threshold tracking transcranial magnetic stimulation (TMS) was used to assess cortical excitability and cognitive function was determined by the Edinburgh Cognitive and Behavioural ALS Screen (ECAS). Cognitive impairment was defined by ECAS &lt; 105. Patients with ALS, defined by the Awaji criteria, were prospectively recruited. Patients unable to undergo TMS, or in whom TMS indices were compromised by coexistent medical conditions, were excluded. Cortical hyperexcitability was defined by reduced short interval intracortical inhibition (SICI) and increased short interval intracortical facilitation (SICF), index of excitability (IE), and motor evoked potential (MEP) amplitude. Student <i>t</i> test determined differences between groups and multivariable regression modeling was used to assess association among cognitive, clinical, and TMS measures. TMS results were compared with those of 42 controls.</AbstractText><AbstractText Label="RESULTS">Cognitive impairment was evident in 36% of the 40 patients with ALS (23 male, mean age 62.1 years). Cortical hyperexcitability was more prominent in cognitively impaired patients as indicated by an increase in SICF (ECAS<sub>&#x2265;105</sub> -15.3 &#xb1; 1.7%, ECAS<sub>&lt;105</sub> -20.6 &#xb1; 1.2%; <i>p</i> &lt; 0.01), IE (ECAS <sub>&#x2265;105</sub> 80.9 &#xb1; 7.8, ECAS <sub>&lt;105</sub> 95.0 &#xb1; 4.5; <i>p</i> &lt; 0.01), and MEP amplitude (ECAS<sub>&#x2265;105</sub> 28.7 &#xb1; 3.3%, ECAS<sub>&lt;105</sub> 43.1 &#xb1; 5.9%; <i>p</i> &lt; 0.05). SICF was independently associated with the ECAS score (<i>&#x3b2;</i> = 2.410; <i>p</i> &lt; 0.05). Reduced SICI was evident in ALS, being more prominent in patients with reduced executive score (ECAS<sub>executive score&gt;33</sub> 6.2 &#xb1; 1.3%, ECAS<sub>executive score&lt;33</sub> 1.5 &#xb1; 2.1%; <i>p</i> &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSION">Cortical hyperexcitability was more prominent in cognitively impaired patients with ALS than in controls. Given that ECAS is a valid predictor of TDP-43 pathology, the increase in cortical hyperexcitability may be associated with TDP-43 accumulation.</AbstractText><CopyrightInformation>&#xa9; 2021 American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Higashihara</LastName><ForeName>Mana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavey</LastName><ForeName>Nathan</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Bos</LastName><ForeName>Mehdi</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0381-917X</Identifier><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Parvathi</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiernan</LastName><ForeName>Matthew C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vucic</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>From the Westmead Clinical School (M.H., N.P., M.v.d.B., P.M., S.V.) and Brain and Mind Centre (M.C.K.), University of Sydney, Australia; Department of Neurology (M.H.), Tokyo Metropolitan Geriatric Hospital, Japan; and Department of Neurology (M.C.K.), Royal Prince Alfred Hospital, Sydney, Australia. steve.vucic@sydney.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002540" MajorTopicYN="N">Cerebral Cortex</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="N">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>8</Day><Hour>5</Hour><Minute>51</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33827958</ArticleId><ArticleId IdType="doi">10.1212/WNL.0000000000011798</ArticleId><ArticleId IdType="pii">WNL.0000000000011798</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>